Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory Turnover for the
six
months ended in Dec. 2025 was 1.16.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.20.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biocytogen Pharmaceuticals (Beijing) Co's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Biocytogen Pharmaceuticals (Beijing) Co Days Inventory Related Terms
Biocytogen Pharmaceuticals (Beijing) Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co Days Inventory Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co Days Inventory vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Days Inventory of 157.87 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. This is 21% below median its historical median of 200.90. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's Days Inventory has ranged from 147.03 to 260.73. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #263 out of 638 companies in the Biotechnology industry, placing it in the top 41.2%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Days Inventory too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Days Inventory of 157.87 is 21% below median its 10-year median of 200.90. Over the past 10 years, this metric has ranged from a low of 147.03 to a high of 260.73. The Biotechnology industry median Days Inventory is 183.20. Biocytogen Pharmaceuticals (Beijing) Co's value of 157.87 is 13.8% below this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #263 out of 638 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #263 out of 638 companies for Days Inventory. This puts Biocytogen Pharmaceuticals (Beijing) Co in the upper half of its industry. The industry median Days Inventory is 183.20. Biocytogen Pharmaceuticals (Beijing) Co's value of 157.87 is 13.8% below this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own Days Inventory has ranged from 147.03 to 260.73 over the past decade. While the company's 10-year median is 200.90 vs. the industry median of 183.20, Biocytogen Pharmaceuticals (Beijing) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current Days Inventory of 157.87 is 13.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Biocytogen Pharmaceuticals (Beijing) Co and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current Days Inventory is 157.87, which is 21% below median its own 10-year median of 200.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.51, compared to a current price of €5.80 — trading 65.2% above its estimated fair value. The current Days Inventory is 157.87, which is 21% below median its 10-year median of 200.90 and 13.8% below the Biotechnology industry median of 183.20. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Days Inventory is 157.87 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €5.80 is trading 65.2% above its estimated GF Value™ of €3.51.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
Days Inventory: 157.87 (21% below median its 10-year median of 200.90)
GF Value™: €3.51 vs. price of €5.80 (65.2% above fair value)
Industry Position: 13.8% below the Biotechnology median (#263 of 638)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Business Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
80GF Score
Get the complete analysis for FRA:I54
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
